Open AccessA phase III, randomized, open-label study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy in patients with metastatic castration-resistant prostate cancer
Author(s) -
Neeraj Agarwal,
Arun Azad,
Joan Carles,
Simon Chowdhury,
Bradley A. McGregor,
Axel S. Merseburger,
Stéphane Oudard,
Fred Saad,
Andrey Soares,
Fawzi Benzaghou,
Yannick Kerloëguen,
Akiko Kimura,
Nehal Mohamed,
Ashok Panneerselvam,
Fong Wang,
Sumanta K. Pal
Publication year - 2022
Publication title -
future oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.857
H-Index - 72
eISSN - 1744-8301
pISSN - 1479-6694
DOI - 10.2217/fon-2021-1096
Subject(s) - cabozantinib , medicine , atezolizumab , prostate cancer , enzalutamide , oncology , clinical trial , cancer , nivolumab , immunotherapy , androgen receptor
Cabozantinib inhibits multiple receptor tyrosine kinases, including the TAM kinase family, and may enhance response to immune checkpoint inhibitors. One cohort of the ongoing phase Ib COSMIC-021 study (NCT03170960) evaluating cabozantinib plus the PD-L1 inhibitor atezolizumab in men with metastatic castration-resistant prostate cancer (mCRPC) that has progressed in soft tissue on/after enzalutamide and/or abiraterone treatment for metastatic disease has shown promising efficacy. Here, we describe the rationale and design of a phase III trial of cabozantinib plus atezolizumab versus a second novel hormone therapy (NHT) in patients who have previously received an NHT for mCRPC, metastatic castration-sensitive PC or nonmetastatic CRPC and have measurable visceral disease and/or extrapelvic adenopathy – a population with a significant unmet need for treatment options. Trial Registration Clinical Trial Registration: NCT04446117 (ClinicalTrials.gov) Registered on 24 June 2020.